波生坦治疗特发性肺动脉高压的疗效与安全性观察

目的:探讨波生坦治疗特发性肺动脉高压(IPAH)的疗效与安全性。方法:16例IPAH患者予波生坦口服治疗20周,比较治疗前后患者心功能、6分钟步行距离(6MWD)、肺动脉压力以及血常规、肝肾功能变化。结果:患者心功能由治疗前Ⅲ级13例、Ⅳ级3例变为Ⅱ级14例、Ⅲ级2例。6MWD较治疗前明显延长(P<0.01),肺动脉收缩压、肺动脉平均压及肺动脉舒张压均较治疗前显著降低(P<0.01),患者血常规、肝肾功能较治疗前无明显变化。结论:口服波生坦治疗IPAH可明显改善患者的临床症状与血流动力学指标,安全性好。

Clinical Efficacy and Safety of Bosentan Therapy for Idiopathic Pulmonary Arterial Hypertension

Objective: To investigate the efficacy and safety on the treatment of bosentan in idiopathic pulmonary arterial hypertension(IPAH).Methods: 16 patients with IPAH were treated with oral bosentan for 20 weeks.Cardiac function,6-minute walk distance(6MWD),pulmonary artery pressure,liver and kidney function changes were compared before and after the treatment.Results: After treatment,13 cases with grade Ⅲ and 3 cases with grade Ⅳ of cardiac function turned into 14 cases with grade Ⅱ and 2 cases with grade Ⅲ.6MWD was significantly longer than that before treatment(P<0.01).Pulmonary artery systolic pressure,mean pulmonary artery pres-sure and pulmonary artery diastolic pressure was significantly lower than before treatment(P<0.01).There were no significant changes in liver and kidney function of the patients before and after treatment.Conclusions: Oral bosentan therapy in patients with IPAH can signifi-cantly improve the clinical symptoms and hemodynamics,which has good security.